Clostridioides difficile is the most important cause of healthcare-associated diarrhea in the
United States. The high incidence and recurrence rates of C. difficile infection (CDI) …

Despite an increased incidence of Clostridioides difficile infections, data on the reservoirs
and dissemination routes of this bacterium are limited. This study examined the prevalence …

Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which
often stems from disruption of the gut microbiota by broad-spectrum antibiotics. The …

Clostridioides difficile is the most common cause of antibiotic-associated diarrhoea globally.
Its spores have been implicated in the prevalence of C. difficile infection due to their …

Antibiotic resistance has become a global issue. The most significant risk is the acquisition
of these mechanisms by pathogenic bacteria, which can have a severe clinical impact and …

Objectives To determine the frequencies and clonal distributions of putative genetic
determinants of resistance to antimicrobials applied for treatment of Clostridioides difficile …

Background Our previous study reported a high rate of recurrence in children with
Clostridioides difficile (C. difficile) infection (CDI) after conventional antibiotic therapy. Here …

Objectives Clostridioides difficile epidemiology is evolving with country-associated emerging
and resistant ribotypes (RT). Antimicrobial susceptibility testing of C. difficile isolated from …

Antimicrobial resistance is emerging in clinical strains of Clostridioides difficile. Ibezapolstat
(IBZ) is a DNA polymerase IIIC inhibitor that has completed phase II clinical trials. IBZ has …

Clostridioides difficile infection (CDI) remains a significant healthcare burden. Non-toxigenic
C. difficile (NTCD) strains have shown a benefit in preventing porcine enteritis and in human …